In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells

Although sorafenib has been approved for treating hepatocellular carcinoma (HCC), clinical results are not satisfactory. Polypharmacology (one drug with multiple molecular targets) is viewed as an attractive strategy for identifying novel mechanisms of a drug and then rationally designing more-effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tsang-Pai, Hong, Yi-Han, Yang, Pei-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689675/
https://www.ncbi.nlm.nih.gov/pubmed/29156785
http://dx.doi.org/10.18632/oncotarget.21030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689675/
https://www.ncbi.nlm.nih.gov/pubmed/29156785
http://dx.doi.org/10.18632/oncotarget.21030

Ejemplares similares